Search results
Showing 1201 to 1215 of 1397 results for 0
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months after treatment with rituximab or a rituximab-containing regimen in adults.
Etanercept and efalizumab for treating moderate to severe plaque psoriasis (TA103)
Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults.
This guideline covers recognising and responding to abuse and neglect in children and young people aged under 18. It covers physical, sexual and emotional abuse, and neglect. The guideline aims to help anyone whose work brings them into contact with children and young people to spot signs of abuse and neglect and to know how to respond. It also supports practitioners who carry out assessments and provide early help and interventions to children, young people, parents and carers.
This guideline covers needle and syringe programmes for people (including those under 16) who inject drugs. The main aim is to reduce the transmission of viruses and other infections caused by sharing injecting equipment, such as HIV, hepatitis B and C. In turn, this will reduce the prevalence of blood-borne viruses and bacterial infections, so benefiting wider society.
This guideline covers the rapid identification and early management of major trauma in pre-hospital and hospital settings, including ambulance services, emergency departments, major trauma centres and trauma units. It aims to reduce deaths and disabilities in people with serious injuries by improving the quality of their immediate care. It does not cover care for people with burns.
Digital technologies to support self-management of COPD: early value assessment (HTG736)
Early value assessment (EVA) guidance on digital technologies to support self-management of COPD.
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts (TA399)
Evidence-based recommendations on azacitidine (Vidaza) for treating acute myeloid leukaemia with more than 30% bone marrow blasts.
Evidence-based recommendations on ciclosporin (Ikervis) for dry eye disease in adults that has not improved despite treatment with artificial tears.
Evidence-based recommendations on pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.
NICE has developed a medtech innovation briefing (MIB) on Permacol for treating anal fistulae .
NICE has developed a medtech innovation briefing (MIB) on Biopatch for venous or arterial catheter sites .
NICE has developed a medtech innovation briefing (MIB) on Fungitell for antifungal treatment stratification .
NICE has developed a medtech innovation briefing (MIB) on the ATEC breast biopsy system
NICE has developed a medtech innovation briefing (MIB) on Mobi-C for cervical disc replacement
Mersey Burns for calculating fluid resuscitation volume when managing burns (MIB58)
NICE has developed a medtech innovation briefing (MIB) on Mersey Burns for calculating fluid resuscitation volume when managing burns